Allergan Aesthetics has announced positive topline results from a clinical trial evaluating Botox Cosmetic (onabotulinumtoxinA) for the treatment of platysma prominence, a condition characterized by visible vertical neck bands that become more pronounced with age. The cosmetic application targets the platysma muscle in the neck, potentially offering patients a non-surgical option for addressing aesthetic concerns in this challenging area.
The platysma muscle is a thin, sheet-like muscle extending from the chest up to the jawline. As skin loses elasticity and the muscle weakens over time, prominent vertical bands can form, creating an aged or strained appearance in the neck region. These bands are particularly noticeable during facial expressions or when the neck is flexed, making them a common cosmetic concern for aging patients.
While specific efficacy data and patient numbers from the trial have not yet been disclosed, the company’s characterization of the results as “positive” suggests the treatment met its primary endpoints. Botox Cosmetic works by temporarily blocking nerve signals to targeted muscles, causing them to relax and reducing the appearance of dynamic wrinkles and muscle bands. The product is already FDA-approved for multiple cosmetic indications, including frown lines, crow’s feet, and forehead lines.
If approved for platysma prominence, this would expand Botox Cosmetic’s reach into the neck aesthetics market, an area that has historically presented challenges for non-invasive treatments. Currently, patients seeking improvement in neck appearance often turn to surgical options such as neck lifts or platysmaplasty, which involve longer recovery times and higher costs than injectable treatments.
The development could offer clinicians and patients a minimally invasive alternative with the established safety profile of Botox Cosmetic. As the aesthetic medicine market continues to grow, particularly among patients seeking preventative and maintenance treatments, additional approved indications for existing neuromodulators may reshape treatment approaches for facial and neck aging.